Transition Zone PSA Density Does Not Improve Detection of Clinically Significant Prostate Cancer over Whole-Gland PSA Density: A Volume-Stratified Analysis in 3,958 Patients

Le résumé fourni par la source

INTRODUCTION: Transition zone PSA density (TZ-PSAD) was proposed to improve prostate cancer detection by normalizing PSA to the compartment most affected by benign prostatic hyperplasia (BPH). If valid, TZ-PSAD should provide the greatest benefit in large prostates where BPH predominates. We tested this assumption across prostate volume categories in the largest MRI-based cohort reported to date. MATERIALS AND METHODS: We analyzed 3,958 consecutive patients who underwent multiparametric MRI with manual zonal segmentation and combined MRI-guided targeted plus systematic transperineal biopsy (March 2010-June 2025). Diagnostic accuracy of TZ-PSAD versus whole-gland PSAD was compared using receiver operating characteristic analysis with DeLong testing. Volume-stratified subgroup analysis (<30 mL, 30-50 mL, and >50 mL) assessed performance consistency. Clinical utility was evaluated by decision curve analysis (DCA). RESULTS: Of 3,958 patients, 1,629 (41.2%) had clinically significant prostate cancer (International Society of Urological Pathology grade group: ≥2). TZ-PSAD achieved marginally superior area under the curve (AUC) (0.768 vs. 0.758, p < 0.001; ΔAUC 0.010). Volume-stratified analysis revealed inconsistent performance: TZ-PSAD was inferior in small prostates (<30 mL: ΔAUC -0.017, p = 0.015), modestly beneficial at intermediate volumes (30-50 mL: ΔAUC +0.013, p = 0.026), and nonsignificant in large glands (>50 mL: ΔAUC +0.006, p = 0.462). DCA confirmed fewer than 1 additional cancer detected per 1,000 patients at clinically relevant thresholds. Limitations include the retrospective single-center design, absence of PI-RADS-stratified analysis, and incomplete capture of 5-alpha reductase inhibitor exposure. CONCLUSION: TZ-PSAD fails to outperform whole-gland PSAD in prostates >50 mL, where its theoretical rationale is strongest. The additional complexity of zonal segmentation is not justified for routine clinical use.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.